I appreciate that everyone has different opinions but i still struggle to see how this is a positive and has derisked things? If CGB had acquired medcan, they would own their own full suite of licences and wouldn't need to pay other companies to grow and manufacture for them.. i believe it has made it far more risky. If they owned the licences themselves they could always fall back on those alone for a use in the industry. What happens if biohealth pull out of the deal? Where would that leave CGB? I also just had a thought.. bio health dont have an ODC medicinal cannabis manufacture licence. They are licenced to make capsules, powders etc etc products.. but no mention of cannabis licences, which they obviously require. Or have i missed something? On top of that, i still dont see where they're going to set their plant material from. Even if it is medcan (i doubt it will be... not for cheap anyway), arent you guys saying they're still years off having the facilties up and running?
